IL130094A - Compounds 2 - imidazolinylaminobenzoxazole used as agonists of alpha-adrenoreceptor 2 - and pharmaceutical preparations containing them - Google Patents

Compounds 2 - imidazolinylaminobenzoxazole used as agonists of alpha-adrenoreceptor 2 - and pharmaceutical preparations containing them

Info

Publication number
IL130094A
IL130094A IL13009497A IL13009497A IL130094A IL 130094 A IL130094 A IL 130094A IL 13009497 A IL13009497 A IL 13009497A IL 13009497 A IL13009497 A IL 13009497A IL 130094 A IL130094 A IL 130094A
Authority
IL
Israel
Prior art keywords
dosage range
compounds
usp
alpha
mmol
Prior art date
Application number
IL13009497A
Other languages
English (en)
Hebrew (he)
Other versions
IL130094A0 (en
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of IL130094A0 publication Critical patent/IL130094A0/xx
Publication of IL130094A publication Critical patent/IL130094A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL13009497A 1996-11-25 1997-11-21 Compounds 2 - imidazolinylaminobenzoxazole used as agonists of alpha-adrenoreceptor 2 - and pharmaceutical preparations containing them IL130094A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3178796P 1996-11-25 1996-11-25
PCT/US1997/020803 WO1998023611A1 (en) 1996-11-25 1997-11-21 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists

Publications (2)

Publication Number Publication Date
IL130094A0 IL130094A0 (en) 2000-02-29
IL130094A true IL130094A (en) 2001-09-13

Family

ID=21861392

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13009497A IL130094A (en) 1996-11-25 1997-11-21 Compounds 2 - imidazolinylaminobenzoxazole used as agonists of alpha-adrenoreceptor 2 - and pharmaceutical preparations containing them

Country Status (18)

Country Link
US (1) US6110952A (de)
EP (1) EP0944622A1 (de)
JP (1) JP2001506601A (de)
KR (1) KR20000069128A (de)
AU (1) AU736992B2 (de)
BR (1) BR9713537A (de)
CA (1) CA2272683A1 (de)
CO (1) CO4910150A1 (de)
CZ (1) CZ183699A3 (de)
HU (1) HUP0002966A3 (de)
ID (1) ID22060A (de)
IL (1) IL130094A (de)
NO (1) NO313755B1 (de)
PE (1) PE16599A1 (de)
SK (1) SK74999A3 (de)
TR (1) TR199901486T2 (de)
WO (1) WO1998023611A1 (de)
ZA (1) ZA9710579B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2272683A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
WO2000051625A1 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
JP2008515990A (ja) * 2004-10-13 2008-05-15 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス抑制のための化合物およびその使用方法
EP2218442A1 (de) 2005-11-09 2010-08-18 CombinatoRx, Inc. Verfahren, Zusammensetzungen und Kits zur Behandlung von ophthalmologischen Erkrankungen
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US8080550B2 (en) * 2008-08-01 2011-12-20 Alpha Synergy Development, Inc. Anesthetic compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
WO2010074753A1 (en) * 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
CA2843245A1 (en) * 2011-07-25 2013-01-31 Allergan, Inc. N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US3830804A (en) * 1972-11-20 1974-08-20 Eastman Kodak Co Fluorescent(pyrimidinotriazolyl)-2-styrylbenzoxazoles
US4398028A (en) * 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
FR2521140A1 (fr) * 1982-02-05 1983-08-12 Synthelabo Derives d'imidazolidine, leur preparation et leur application en therapeutique
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
GB9110017D0 (en) * 1991-05-09 1991-07-03 Nat Res Dev Spectroscopic investigation using organometallic compounds
EP0741709B1 (de) * 1994-01-24 2001-07-25 Allergan Sales, Inc. Aromatische 2-amino-imidazolderivate als alpha 2a-adrenoceptor agonisten
EP0775134A4 (de) * 1994-08-04 1997-08-13 Synaptic Pharma Corp Neue benzimidazolderivate
KR100215541B1 (ko) * 1996-04-19 1999-08-16 박원훈 벤족사졸계 비선형 광학 유도체 및 이들로부터 얻어진고분자
CA2272683A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists

Also Published As

Publication number Publication date
NO992500L (no) 1999-07-26
SK74999A3 (en) 2000-02-14
AU736992B2 (en) 2001-08-09
HUP0002966A3 (en) 2001-10-29
JP2001506601A (ja) 2001-05-22
PE16599A1 (es) 1999-03-12
AU5438298A (en) 1998-06-22
EP0944622A1 (de) 1999-09-29
BR9713537A (pt) 2000-03-21
CO4910150A1 (es) 2000-04-24
NO313755B1 (no) 2002-11-25
KR20000069128A (ko) 2000-11-25
IL130094A0 (en) 2000-02-29
TR199901486T2 (xx) 1999-10-21
CA2272683A1 (en) 1998-06-04
WO1998023611A1 (en) 1998-06-04
US6110952A (en) 2000-08-29
ID22060A (id) 1999-08-26
NO992500D0 (no) 1999-05-25
HUP0002966A2 (hu) 2001-09-28
CZ183699A3 (cs) 1999-09-15
ZA9710579B (en) 1998-06-25

Similar Documents

Publication Publication Date Title
EP0944621B1 (de) 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten
US6117871A (en) 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US6225331B1 (en) Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
US5965595A (en) 2-Imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US5916900A (en) 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5804587A (en) 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists
US6110952A (en) 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
US5914342A (en) 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US6306877B1 (en) Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6172095B1 (en) Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
EP0944601B1 (de) Guanidinylamino-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
EP0975627A1 (de) 5-(2-imidazolinylamino)benzimidazol-verbindungen zur verwendung als alpha-2-andrenoceptor-agonisten
AU5433998A (en) 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonis ts
WO1998023612A1 (en) 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees